| Survey of Inhibitors in Plasma-Product Exposed Toddlers (NCT01064284) | Fondazione Angelo Bianchi Bonomi | 2010-01-01 |
| Quality of Life Study of Helixate NexGen (NCT01053715) | CSL Behring | 2010-01-01 |
| Efficacy and Safety of IL-11 in DDAVP Unresponsive (NCT00994929) | University of Pittsburgh | 2010-01-01 |
| Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A (NCT01029340) | Bayer | 2009-12-01 |
| Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients (NCT00914459) | Pfizer | 2009-12-01 |
| Study of Ataluren (PTC124) in Hemophilia A and B (NCT00947193) | PTC Therapeutics | 2009-10-14 |
| Health Related Quality of Life of Youth and Young Adults With Hemophilia A (NCT01034904) | CSL Behring | 2009-10-01 |
| Individually Tailored Prophylaxis in Patients With Severe Hemophilia A (NCT00995046) | Hospices Civils de Lyon | 2009-09-01 |
| Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America (NCT00969319) | Bayer | 2009-09-01 |
| Study Evaluating Pharmacovigilance Of Refacto AF (NCT00895037) | Pfizer | 2009-07-17 |
| Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A (NCT00916032) | Baxalta now part of Shire | 2009-06-29 |
| Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens (NCT00927667) | Bayer | 2009-06-01 |
| Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age (NCT00759655) | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-06-01 |
| Efficacy and Safety of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With Hemophilia (NCT00797381) | Shanghai Public Health Clinical Center | 2009-05-01 |
| Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings (NCT00884390) | Pfizer | 2009-05-01 |
| EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan (NCT00932555) | Bayer | 2009-04-01 |
| Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor (NCT00851721) | Baxalta now part of Shire | 2009-03-31 |
| Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A (NCT00879541) | CSL Behring | 2009-02-01 |
| Study Evaluating The Safety Of Xyntha In Usual Care Settings (NCT00765726) | Pfizer | 2009-02-01 |
| Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors (NCT01921855) | Bayer | 2009-01-01 |
| Gait Evaluation in Haemophiliac Patients (NCT00824798) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2009-01-01 |
| Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects (NCT00868530) | Pfizer | 2008-09-01 |
| Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection (NCT00952822) | Baxalta now part of Shire | 2008-08-08 |
| Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery (NCT00922597) | Bayer | 2008-08-01 |
| Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A (NCT00717626) | The Hospital for Sick Children | 2008-07-01 |
| EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS (NCT00874926) | Bayer | 2008-06-01 |
| BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A (NCT00623727) | Bayer | 2008-06-01 |
| Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A (NCT00666406) | Baxalta now part of Shire | 2008-03-31 |
| Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment (NCT00623480) | Bayer | 2008-03-01 |
| Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study (NCT00936312) | Weill Medical College of Cornell University | 2008-03-01 |
| Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII (NCT00543439) | Pfizer | 2007-12-01 |
| Study Evaluating Approach to Treatment of Haemophilia A and B in Spain (NCT00581438) | Wyeth is now a wholly owned subsidiary of Pfizer | 2007-06-01 |
| Russian Kogenate Pediatric Study (NCT00632814) | Bayer | 2007-06-01 |
| Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay (NCT00839202) | Children's Hospital Los Angeles | 2006-09-01 |
| Rituximab to Treat Severe Hemophilia A (NCT00331006) | Carelon Research | 2006-06-01 |
| Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery (NCT00357656) | Baxalta now part of Shire | 2006-05-29 |
| Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A (NCT00621673) | Bayer | 2006-05-01 |
| Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery (NCT00243659) | Wyeth is now a wholly owned subsidiary of Pfizer | 2006-04-01 |
| Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A (NCT00306670) | Georgetown University | 2006-04-01 |
| Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A (NCT00289536) | Baxalta now part of Shire | 2006-02-02 |
| BAY14-2222 Prophylaxis and Joint Function Improvement (Adults) (NCT00586521) | Bayer | 2006-02-01 |
| Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A (NCT00243386) | Baxalta now part of Shire | 2006-01-04 |
| Clot Formation and Clot Stability in Patients With Severe Haemophilia A (NCT00279578) | University of Aarhus | 2006-01-01 |
| Study Evaluating Inhibitor Specificity in Hemophilia A (NCT00151385) | Wyeth is now a wholly owned subsidiary of Pfizer | 2005-11-01 |
| Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A (NCT00141843) | Wyeth is now a wholly owned subsidiary of Pfizer | 2005-07-01 |
| The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs (NCT00212459) | New York Presbyterian Hospital | 2005-05-01 |
| Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII (NCT00245245) | Octagen Corporation | 2005-05-01 |
| Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study (NCT00936845) | Weill Medical College of Cornell University | 2005-04-01 |
| Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A (NCT00168051) | Wyeth is now a wholly owned subsidiary of Pfizer | 2005-04-01 |
| Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101 (NCT00189982) | Baxalta now part of Shire | 2004-12-17 |
| Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A (NCT01568580) | Green Cross Corporation | 2004-12-01 |
| ADVATE Post Authorization Safety Surveillance (NCT00214734) | Baxalta now part of Shire | 2004-10-14 |
| Prophylaxis Versus On-demand Therapy Through Economic Report (NCT01159587) | Bayer | 2004-07-01 |
| Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients (NCT00157157) | Baxalta now part of Shire | 2004-04-01 |
| Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients (NCT00162019) | Baxalta now part of Shire | 2003-03-31 |
| Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery (NCT00092976) | Wyeth is now a wholly owned subsidiary of Pfizer | 2003-02-01 |
| International PMS Study - KOGENATE Bayer (NCT00864552) | Bayer | 2002-12-01 |
| Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia (NCT00178607) | The University of Texas Health Science Center, Houston | 2002-08-01 |
| Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A (NCT00157040) | Baxalta now part of Shire | 2002-06-07 |
| Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901 (NCT00157053) | Baxalta now part of Shire | 2001-11-22 |
| Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery (NCT00157105) | Baxalta now part of Shire | 2001-02-12 |
| Hepatitis C in Clinically Discordant Hemophilic Siblings (NCT00007371) | University of North Carolina, Chapel Hill | 1999-09-01 |
| Study Evaluating Refacto For Pharmacovigilance (NCT00195442) | Wyeth is now a wholly owned subsidiary of Pfizer | 1999-07-01 |
| Epidemiology and Immunology of Hemophilia A Inhibitors (NCT00005518) | National Heart, Lung, and Blood Institute (NHLBI) | 1998-06-01 |
| Joint Outcome Study (NCT00207597) | Centers for Disease Control and Prevention | 1995-09-01 |
| Study Evaluating ReFacto in Hemophilia A (NCT00038909) | Wyeth is now a wholly owned subsidiary of Pfizer | 1994-09-01 |
| Prospective Study of HIV Infection in Hemophiliacs (NCT00005309) | Bloodworks | 1990-07-01 |
| Hepatitis Delta Infections in Hemophiliacs (NCT00005305) | University of North Carolina, Chapel Hill | 1987-09-01 |
| Delta Hepatitis and Liver Disease in Hemophiliacs (NCT00005304) | Baylor College of Medicine | 1986-09-01 |
| Cooperative Study of Factor VIII Inhibitors (NCT00000582) | National Heart, Lung, and Blood Institute (NHLBI) | 1978-07-01 |
| Study Evaluating ReFacto AF in Severe Hemophilia A (NCT00037544) | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A (NCT00038935) | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia (NCT00002386) | Merck Sharp & Dohme LLC | |
| Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients With Hemophilia (NCT00000705) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Effects of AZT and Ibuprofen on HIV-Infected Patients With Hemophilia (NCT00002276) | University of Pittsburgh | |
| The Influence of "Karate" on Bleeding in Hemophilic Patients. (NCT00281333) | Sheba Medical Center | |
| Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation (NCT00375323) | Medical University of Vienna | |
| An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors (NCT03154437) | Genentech, Inc. | |